Benzinga · Aug 17, 2026
Indaptus Therapeutics Files Prospectus Related To The Proposed Resale Of Up To 58,895,000 Shares Of Common Stock By Selling Stockholders
https://www.sec.gov/Archives/edgar/data/1857044/000149315226038780/forms-3.htm
IN
NASDAQ · INDP
Indaptus Therapeutics, Inc.
Healthcare · Biotechnology
$2.08
Up+$0.52 (+25.00%)
Updated Sep 10, 2026, 7:58 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 4.47M
- P/E ratio
- -0.09
- Dividend yield
- 0.00%
- 52-week range
- $0.92 – $8.57
- Volume
- 5.68M
- Avg. volume
- 521.72K
Price performance
INDP price history
1M range · 20 trading sessions · Daily adjusted prices
INDP closed at $2.08 after 20 trading sessions, up 103.92% for the selected period.
- Last close
- $2.08
- Period change
- +103.92%
- Period low
- $0.94
- Period high
- $2.08
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $1.92 | $2.39 | $1.89 | $2.08 | 5.68M |
| Sep 8, 2026 | $1.285 | $1.94 | $1.27 | $1.85 | 8.46M |
| Sep 4, 2026 | $1.20 | $1.235 | $1.17 | $1.22 | 133.11K |
| Sep 3, 2026 | $1.16 | $1.19 | $1.14 | $1.16 | 249.92K |
| Sep 2, 2026 | $1.17 | $1.20 | $1.1312 | $1.17 | 331.83K |
| Sep 1, 2026 | $1.10 | $1.162 | $1.10 | $1.13 | 75.3K |
| Aug 31, 2026 | $1.14 | $1.17 | $1.09 | $1.145 | 140.26K |
| Aug 28, 2026 | $1.16 | $1.1845 | $1.10 | $1.14 | 104.08K |
| Aug 27, 2026 | $1.13 | $1.24 | $1.09 | $1.16 | 404.59K |
| Aug 26, 2026 | $1.09 | $1.16 | $1.06 | $1.14 | 206.02K |
| Aug 25, 2026 | $1.15 | $1.18 | $1.09 | $1.095 | 497.16K |
| Aug 24, 2026 | $1.24 | $1.29 | $1.13 | $1.16 | 293.73K |
| Aug 21, 2026 | $1.39 | $1.58 | $1.18 | $1.29 | 1.14M |
| Aug 20, 2026 | $0.9419 | $1.42 | $0.94 | $1.38 | 11.75M |
| Aug 19, 2026 | $0.9361 | $1.11 | $0.925 | $0.94 | 813.18K |
| Aug 18, 2026 | $1.00 | $1.02 | $0.92 | $0.9361 | 341.45K |
| Aug 17, 2026 | $1.10 | $1.24 | $0.9801 | $1.00 | 359.56K |
| Aug 14, 2026 | $1.09 | $1.15 | $1.0201 | $1.07 | 130.85K |
| Aug 13, 2026 | $1.02 | $1.09 | $1.02 | $1.06 | 92.99K |
| Aug 12, 2026 | $1.22 | $1.22 | $1.01 | $1.02 | 276.33K |
Latest INDP news
The latest Smart Investors Daily articles mentioning INDP.
Stock researchCompany · Overview
INDP research
Overview
Company profile and research snapshot.
Company profile
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 13, 2024 | Maxim Group | Buy | — |
| Oct 16, 2024 | HC Wainwright & Co. | Buy | — |
| Jun 17, 2024 | HC Wainwright & Co. | Buy | — |
| Apr 15, 2024 | HC Wainwright & Co. | Buy | — |
| Sep 20, 2023 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 13, 2026
Indaptus Therapeutics Q2 EPS $(0.02) Beats $(1.57) Estimate
Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(1.57) by 98.73 percent. This is a 99.78 percent increase over losses of $(9.09) per share
Benzinga · Jun 26, 2026
Indaptus Therapeutics Files Prospectus Related To The Resale By The Selling Stockholders Of Up To 18.86M Shares Of Common Stock
https://www.sec.gov/Archives/edgar/data/1857044/000149315226030346/forms-3.htm
Benzinga · Jun 24, 2026
Indaptus Therapeutics Entered Stock Sale Agreement To Sell 20M Shares For $0.06/Share; Gross Proceeds Of $12M
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001857044/000149315226029918/form8-k.htm
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
